Capricor Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CAPR research report →
About the company
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
- CEO
- Linda Marbán
- IPO
- 2007
- Employees
- 231
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $1.06B
- P/E
- -10.00
- P/S
- 0.00
- P/B
- 4.78
- EV/EBITDA
- 1.09
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -59.27%
- ROIC
- -40.00%
- Revenue
- $0 · -100.00%
- Net Income
- $-105,043,946 · -159.58%
- EPS
- $-2.26 · -96.52%
- Op Income
- $-108,142,130
- FCF YoY
- -75.07%
- 52W High
- $40.37
- 52W Low
- $4.30
- 50D MA
- $29.25
- 200D MA
- $22.30
- Beta
- 0.42
- Avg Volume
- 1.16M
Get TickerSpark's AI analysis on CAPR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 25, 26 | Krasney Karen | other | 24,100 |
| Jun 25, 26 | Krasney Karen | other | 24,100 |
| Jun 25, 26 | Krasney Karen | sell | 24,100 |
| Jun 25, 26 | Bergmann Anthony | other | 24,100 |
| Jun 25, 26 | Bergmann Anthony | other | 24,100 |
| Jun 25, 26 | Bergmann Anthony | sell | 24,100 |
| Jun 22, 26 | Krasney Karen | other | 500 |
| Jun 24, 26 | Krasney Karen | other | 400 |
| Jun 22, 26 | Krasney Karen | other | 500 |
| Jun 24, 26 | Krasney Karen | other | 400 |
Our CAPR coverage
Recent articles, reports, and earnings notes.
Vesicor Therapeutics Is Going Public via SPAC — Here’s the Setup
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Should You Buy the Parabilis Medicines IPO? Here's the Setup
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Want a deeper read on CAPR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.